Best Momentum Stocks to Buy for October 13th

The article highlights Repsol, Target and Calumet as Zacks Rank #1 stocks, with current-year earnings consensus estimates up 23.3%, 24.3% and 8.6%, respectively, over the past 60 days. Calumet shares gained 44.5% over the past three months, while the article says the S&P 500 declined 3.8%; Calumet has a Momentum Score of B. This is a stock-screening recommendation, not a report of company results or a market-moving event.

Analysis

The signal here is estimate-revision breadth, not independent evidence of improving cash generation. Revisions can reflect commodity assumptions, FX, or changed analyst models; confirm the drivers and whether operating guidance supports them before paying for momentum.

CLMT has the clearest near-term flow risk: after a sharp run, incremental buyers may be relying on continued estimate upgrades. That makes the setup vulnerable to a guidance disappointment or reversal in renewable-fuel and specialty-chemical economics. Over 1–3 months, realized segment margins and management guidance matter more than the rank label. Over 6–18 months, the key question is whether earnings are durable across the cycle, rather than a favorable period being capitalized as structural growth.

For REP, earnings sensitivity to oil, gas, refining conditions, and currency can make estimate changes less durable; a move in underlying inputs could reverse revisions quickly. For TGT, higher estimates need validation in comparable sales, traffic, and gross margin: stronger earnings driven by cost controls alone may not support lasting multiple expansion if demand remains weak. The article supplies no valuation, revision drivers, or forecast-period detail, so relative attractiveness cannot be established. Contrarian read: the promotional framing and broad performance statistic are not a catalyst; the CLMT move may already discount favorable news, while REP and TGT lack a stated price-momentum case.

Key Decisions for Investors

• Do not buy the basket solely on the rank and revision signal. Before initiating REP or TGT, verify the source of estimate changes, current valuation, and next guidance/earnings dates; treat them as watchlist names until those checks are available.
• Avoid chasing CLMT after its outsized recent advance. Consider a defined-risk bearish position only if momentum breaks and the next update fails to confirm segment economics; options pricing and liquidity must be checked first. A fresh high supported by better realized margins would falsify that tactical short thesis.
• Over the next 1–3 months, monitor REP’s estimate revisions against relevant commodity and refining inputs, and TGT’s comparable sales and gross margin. Revisions reversing or guidance weakening would invalidate the positive signal; sustained operational confirmation would justify reassessing exposure.
• No long/short pair is supported by the information provided: the article gives no comparable valuation, earnings drivers, or forecast detail. Reassess after obtaining those data rather than infer a relative-value trade.